A trial of the cancer injection amivantamab showed it eradicated tumors entirely in 15 of 102 head and neck cancer patients, with overall tumor shrinkage or disappearance in 43 patients whose disease had resisted chemotherapy and immunotherapy. The drug, developed by Johnson & Johnson, works by blocking proteins that help tumors grow and activating the immune system, with researchers calling the results "unprecedented."
Topicle Beta
1 comment
A trial of the cancer injection amivantamab showed it eradicated tumors entirely in 15 of 102 head and neck cancer patients, with overall tumor shrinkage or disappearance in 43 patients whose disease had resisted chemotherapy and immunotherapy. The drug, developed by Johnson & Johnson, works by blocking proteins that help tumors grow and activating the immune system, with researchers calling the results "unprecedented."